source
- Novo outlines plan for multiple new drugs to regain market share as shares dip 8%At a capital markets day in London, Novo executives presented a roadmap to launch more than five multi-blockbuster drugs by 2030 and target $23 billion in annual sales by 2035, aiming to offset the…
- Alkermes' orexin agonist ALKS 7290 shows promise in early-stage ADHD trialAlkermes reported results from a Phase 1 study of its orexin agonist ALKS 7290, a drug class previously explored for rare sleep disorders. The trial enrolled adults with moderate to severe ADHD, a…